No single benzodiazepine is universally “best” for anxiety. The right choice depends on the type of anxiety you have, how quickly you need relief, and how long that relief needs to last. As a class, benzodiazepines are effective for anxiety, with a pooled effect size roughly 50% larger than SSRIs or SNRIs in clinical trials for generalized anxiety disorder. But within the class, the four most commonly prescribed options differ in meaningful ways.
How the Main Options Compare
The benzodiazepines prescribed most often for anxiety disorders are alprazolam (Xanax), lorazepam (Ativan), clonazepam (Klonopin), and diazepam (Valium). They all work through the same basic mechanism, boosting the effect of a calming brain chemical to reduce anxious signaling. What separates them is speed, duration, and which conditions they’re best suited for.
Diazepam acts the fastest, reaching peak effect quickly after you take it. Alprazolam is close behind with a fast-to-intermediate onset. Lorazepam has an intermediate onset, and clonazepam is the slowest to kick in. For someone who needs rapid relief during an acute wave of anxiety, diazepam or alprazolam will feel like they’re working sooner. For someone who needs steady, all-day coverage, that fast onset matters less than how long the drug lasts.
Half-life is where these drugs really diverge. Lorazepam lasts about 10 hours, alprazolam about 12, clonazepam around 18, and diazepam roughly 20 hours (with active metabolites that can extend its effects even longer). A shorter half-life means the drug wears off faster, which can create more noticeable ups and downs throughout the day and require multiple doses. A longer half-life provides smoother coverage but stays in your system longer.
Generalized Anxiety Disorder
For generalized anxiety, the condition characterized by persistent, hard-to-control worry, diazepam and lorazepam have the most clinical trial data. In a large meta-analysis covering 23 trials and over 2,200 participants, benzodiazepines as a class produced a strong treatment effect. Individual trial results show diazepam consistently performing well, with effect sizes ranging from 0.43 to 0.65 across eight studies. Lorazepam showed more variability, ranging from 0.36 to 0.74 across five studies, but included one of the highest single-study results in the entire analysis.
Alprazolam had fewer generalized anxiety trials in the data set, and its results were more scattered. One small study showed an exceptionally high effect size of 1.25, while a larger trial came in at just 0.27. That inconsistency makes it harder to draw firm conclusions about alprazolam specifically for generalized anxiety, though it clearly works for many people.
Panic Disorder
Panic disorder is where alprazolam and clonazepam have the strongest track records. Both are FDA-approved for this use. In a head-to-head trial of 72 patients with panic disorder, both drugs significantly reduced the frequency of panic attacks, overall phobia ratings, and disability compared to placebo. The study found no meaningful difference between the two.
The practical difference comes down to dosing convenience. Clonazepam’s longer half-life (18 hours) means most people can take it once or twice a day and maintain steady coverage. Alprazolam’s 12-hour half-life often requires dosing three times daily, and some people experience rebound anxiety between doses as blood levels drop. For panic disorder specifically, clonazepam’s smoother pharmacokinetic profile gives it a practical edge for many patients.
Social Anxiety Disorder
Clonazepam has the most evidence for social anxiety. In clinical use, roughly 80% of patients with social phobia (both the generalized and performance-specific types) responded to clonazepam treatment. Importantly, this benefit appeared independent of whether patients also had panic disorder, suggesting clonazepam has a direct effect on social anxiety rather than just reducing panic symptoms that overlap with it.
Some people use a short-acting benzodiazepine like alprazolam or lorazepam on an as-needed basis before specific anxiety-provoking situations, like public speaking. This approach limits overall drug exposure but doesn’t address the ongoing, daily burden of generalized social anxiety the way a longer-acting option can.
Why Half-Life Matters for Withdrawal
All benzodiazepines carry real risks of physical dependence, and the FDA requires a boxed warning on every benzodiazepine prescription highlighting the dangers of abuse, addiction, physical dependence, and withdrawal. But these risks aren’t identical across the class.
Dependence develops faster with high-potency, short-acting benzodiazepines. A patient taking a high dose of alprazolam can develop physiological dependence in as little as one to two months. Someone on a lower dose of a longer-acting agent will generally take longer to reach that point. The timeline for withdrawal symptoms also tracks with half-life: shorter-acting drugs produce withdrawal symptoms sooner after the last dose, and those symptoms tend to feel more intense. Longer-acting drugs taper themselves more gradually as they leave the body, which can make withdrawal somewhat less abrupt.
This is one reason many clinicians prefer clonazepam or diazepam for patients who need ongoing benzodiazepine treatment. The smoother blood-level curve means fewer peaks and troughs, less interdose anxiety, and a generally easier eventual taper. Alprazolam, despite being the most widely prescribed benzodiazepine in the United States, is often considered the hardest to stop taking precisely because of its short duration and high potency.
Benzodiazepines vs. First-Line Treatments
Benzodiazepines work faster than SSRIs or SNRIs, which typically take four to six weeks to reach full effect. That speed is their main advantage, and it’s why they’re often prescribed as a bridge while a longer-term medication builds up in your system. In clinical practice, patients with panic disorder receive a benzodiazepine as their first treatment far more often than guidelines recommend, sometimes delaying SSRI treatment by years.
But the meta-analytic data is clear that benzodiazepines produce larger short-term anxiety reductions than either SSRIs or SNRIs. The pooled effect size for benzodiazepines (0.50) was significantly higher than for SSRIs (0.33) or SNRIs (0.36) in generalized anxiety trials. The tradeoff is that SSRIs and SNRIs don’t carry the same dependence risk and are considered safer for long-term use, which is why most treatment guidelines position them as first-line therapy.
Choosing Based on Your Situation
If you’re looking for a simple framework: clonazepam is often the most versatile option. It covers generalized anxiety, panic disorder, and social anxiety with once- or twice-daily dosing, a moderate onset, and a long enough half-life to avoid the interdose anxiety problems common with shorter-acting drugs. Its withdrawal profile, while still serious, is more manageable than alprazolam’s.
Alprazolam makes more sense for people who need fast-acting, short-duration relief for situational anxiety or panic attacks and who won’t be taking it daily for extended periods. Diazepam is a strong choice for generalized anxiety when its long duration is an advantage rather than a drawback. Lorazepam occupies a middle ground and is commonly used in medical settings because of its predictable absorption, but its shorter half-life means more frequent dosing for all-day anxiety coverage.
The “best” benzodiazepine ultimately depends on matching the drug’s profile to your specific anxiety pattern, your tolerance for side effects like sedation, and how long you expect to need treatment. All four options are effective. The differences lie in how they fit into your daily life and how easy they are to eventually stop taking.